National brain tumour research funding needs to increase to £30-35 million a year
Cannabidiol (CBD) oil as a treatment for brain tumours
A new research paper includes scans showing reductions in size for one paediatric and one adult ependymoma. The paper reports on a series of case studies of cancer patients, including a few brain tumour patients, who are under the care of Dr Julian Kenyon of the Dove Clinic. They have been using a synthetic form of pharamaceutical grade cannabidiol (CBD) oil obtained from a UK drugs company called STI Pharmaceuticals, and the paper indicates that this particular product is what made the difference, compared with other oils that can be bought over the internet.
Detailed dosage instructions are included in the data-sf-ec-immutable="">free, full text article ,with Dr Kenyon believing that patients should cycle on and off the oil every three days rather than take a continuous dose. The oil was used for a minimum of six months, and in the adult case, once it was removed, the tumour began to grow again (the patient then returning to the pharmaceutical-grade CBD oil).
Read in more detail on our blog.
- “No evidence of improved survival” with bevacizumab (Avastin) in patients with first recurrence of grade II or III glioma, without 1p/19q co-deletion
- Focused ultrasound to open blood-brain barrier